Intuitive Surgical Zukünftiges Wachstum
Future Kriterienprüfungen 1/6
Intuitive Surgical wird ein jährliches Gewinn- und Umsatzwachstum von 12.6% bzw. 11.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 13.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 15.2% betragen.
Wichtige Informationen
12.6%
Wachstumsrate der Gewinne
13.23%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 16.1% |
| Wachstumsrate der Einnahmen | 11.2% |
| Zukünftige Eigenkapitalrendite | 15.22% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 21 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrativ-Update • May 04
ISRG: Policy Shifts And Platform Adoption Will Shape Balanced Risk Reward Profile
Analysts have trimmed the fair value estimate for Intuitive Surgical by about $8 to $433. This reflects a mix of reduced revenue growth assumptions, slightly different discounting and modestly lower future P/E expectations after a series of both price target cuts and upgrades across the Street.Seeking Alpha • Apr 22
Intuitive Surgical Q1 Earnings Review: Don't Overpay For Quality
Summary Intuitive Surgical delivered strong Q1-2026 results, beating EPS and revenue estimates and slightly raising 2026 guidance. ISRG's robust moat is underpinned by its large installed base, high R&D spending, and dominant position in the fast-growing robotic surgery market. Despite a lower-than-average 47x TTM P/E, ISRG's valuation remains high relative to its expected low-to-mid-teens EPS growth. I maintain a Hold rating, preferring a greater margin of safety before considering a position at current valuation levels. Read the full article on Seeking Alpha
Neues Narrativ • Apr 20
Intuitive Surgical (ISRG): The Digital Surgeon and the "Da Vinci 5" Dominance
Intuitive Surgical (ISRG) , the undisputed pioneer of robotic-assisted surgery, enters Tuesday, April 21, 2026 , following a massive Q1 earnings blowout that reinforces its status as the "Gold Standard" of the operating room. Trading at approximately $482.50 USD —surging nearly 9% in after-hours action —the stock has shattered its previous resistance levels.Narrativ-Update • Apr 20
ISRG: Future Policy Shifts And Platform Adoption Will Shape Premium Multiple
Analysts have trimmed the price target for Intuitive Surgical by about $16 to reflect a slightly higher discount rate and lower assumed future P/E multiple, while maintaining expectations for double digit revenue growth and resilient profit margins supported by a mix of recent target cuts and upgrades across the Street. Analyst Commentary Recent Street research on Intuitive Surgical shows a mix of trimmed price targets and a few upgrades, with most of the action centered on valuation reset rather than drastic changes to fundamental views.
Narrativ-Update • Apr 05
ISRG: Procedure Expansion And Sector Recovery Will Drive 2026 Upside
Analysts have adjusted Intuitive Surgical's price targets in a mixed but generally constructive way, with revisions ranging from cuts at UBS to $550 and $570 to higher targets at firms like Goldman Sachs at $714 and Bernstein at $740. These changes reflect updated views on growth, margins, and the valuation framework around a future P/E near 65.5x.Narrativ-Update • Mar 22
ISRG: Future Platform Adoption And Policy Shifts Will Shape Premium Multiple Sustainability
Intuitive Surgical's updated analyst price target edges lower to $457.50 from $464.58, as analysts balance slightly firmer revenue growth and profit margin assumptions with a modestly lower forward P/E multiple after a mix of recent target cuts and upgrades across the Street. Analyst Commentary Recent research updates on Intuitive Surgical show a mixed backdrop, with several firms trimming price targets even as others reiterate or lift their views.Narrativ-Update • Mar 08
ISRG: Future Platform Adoption And Policy Shifts Will Test Premium Multiple Assumptions
The analyst price target for Intuitive Surgical has been trimmed slightly, with modest shifts in fair value and discount rate inputs as analysts balance lower targets from firms like UBS and Citi against higher targets tied to Dv5 driven growth assumptions and sector recovery themes cited by other firms. Analyst Commentary Recent research on Intuitive Surgical shows a split tape, with some firms lifting targets on the back of Dv5 related growth assumptions and sector recovery themes, while others trim targets and stress execution and valuation risks.
Neues Narrativ • Feb 28
ISRG Riding the Lightning
I have followed ISRG since 2003 when it was brought to the investing club I had just joined. I tried to analyze ISRG with the BetterInvesting SSG methodology that I had been introduced to and I could not get it in the buy zone.
Narrativ-Update • Feb 22
ISRG: Future Returns Will Hinge On Procedure Utilization Versus Sector Rotation Risk
We have raised our Intuitive Surgical fair value estimate by about $15 to $611.82 per share, as analysts factor in slightly higher revenue growth expectations tied to the Dv5 rollout and sector recovery, partly offset by modestly lower margin assumptions. Analyst Commentary Recent Street research around Intuitive Surgical reflects a mix of optimism about growth drivers such as the Dv5 rollout and capital spending trends, alongside more cautious views on valuation and policy risk.Narrativ-Update • Feb 07
ISRG: Future Procedure And Platform Execution Will Test Premium Multiple Assumptions
Analysts nudged their price targets higher on Intuitive Surgical, with a modest fair value move to about $468 per share. They recalibrated assumptions around slightly lower revenue growth, higher profit margins, and a somewhat lower future P/E multiple, following a mix of recent target hikes and trims across the Street.Narrativ-Update • Jan 24
ISRG: Procedure Expansion And Sector Rebound Will Support 2026 Upside
Our Intuitive Surgical fair value estimate edges up to $750 from $740 as analysts recalibrate their price targets around updated growth, margin, and P/E assumptions informed by recent research on procedure trends, Dv5 contributions, and sector re-rating. Analyst Commentary Bullish analysts have been revisiting their models around procedure volumes, adoption of the Dv5 platform, and sector valuation resets.
Narrativ-Update • Jan 18
ISRG at FV
Update on Valuation (18.10.26) Over the next 5 years I calculate with (actual values from 18.01.26 , price/shr at 533 USD ): Revenue Growth p.a.: 12% (Currently at 14,7%) – we saw the peak of revenue growth with nearly 15%, now even 12% is sporty, but with the „abo like“ revenues from spare parts and software licences, based on a still growing bases of installed systems, realisitc. Profit Margin: 30% (currently at 28,6%) - because spare parts in general have more margin then system sales, and the sales out of spare parts is still growing.Narrativ-Update • Jan 10
ISRG: Dv5 Platform Rollout And Rising Procedure Volumes Will Drive 2026 Upside
Analysts have lifted their fair value estimate for Intuitive Surgical to US$740 from US$675, reflecting higher expected profit margins and a somewhat lower future P/E multiple. This change is supported by recent target increases tied to the da Vinci 5 rollout, stronger procedure trends and a more constructive view on healthcare into 2026.Narrativ-Update • Dec 24
ISRG: Elevated Expectations Will Expose Premium Pricing To Utilization And Margin Disappointments
Analysts have raised their price targets on Intuitive Surgical by roughly $50-$60 per share, citing stronger than expected Q3 revenue and EPS growth, improving profitability despite tariff and mix headwinds, and encouraging trends in system utilization that support a higher fair value of about $468 per share, even as valuation remains a key consideration. Analyst Commentary Recent Street research on Intuitive Surgical reflects a mix of optimism on the company’s operational momentum and caution around valuation and risk-reward.Narrativ-Update • Dec 10
ISRG: Future Returns Will Depend On Utilization Strength Versus Sector Volatility
Analysts nudged their average price target on Intuitive Surgical higher by about $3 to roughly $596, citing stronger than expected Q3 profitability, robust demand, and encouraging utilization trends that more than offset lingering concerns about valuation and sector volatility. Analyst Commentary Analyst reactions to the quarter highlight a mix of optimism around execution and utilization trends alongside lingering concerns about valuation and sector sentiment.Narrativ-Update • Nov 26
ISRG: Future Direction Will Balance Demand Strength Against Persistent Sector Volatility
Analysts modestly raised their price targets for Intuitive Surgical, with recent updates clustering in the $525 to $603 range. They cited stronger-than-expected quarterly results and robust demand supporting profitability, despite ongoing sector volatility.Narrativ-Update • Nov 12
ISRG: Future Performance Will Depend On Execution Amid Competitive Pressures
The consensus analyst price target for Intuitive Surgical saw a modest revision, decreasing slightly by $1 to $592.96. Analysts cited solid Q3 performance, ongoing profitability, and mixed expectations around future risks and valuation.Narrativ-Update • Oct 29
Rising Demand And Cost Pressures Will Shape Robotic Surgery Outlook
The analyst price target for Intuitive Surgical has been raised from $573.55 to $594.29. Analysts cite strong third-quarter earnings, improving profit margins, and robust demand, despite ongoing pressures and competitive risks.Narrativ-Update • Oct 14
Emerging Markets Will Expand Robotic-Assisted Surgery Adoption
Analysts have slightly lowered their fair value estimate for Intuitive Surgical to $573.55 from $582.10. They cite mixed views on sales momentum and margin sustainability, despite ongoing strength in fundamentals and recent earnings.Analyseartikel • Sep 09
The Returns At Intuitive Surgical (NASDAQ:ISRG) Aren't Growing
There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'll want to see a...Analyseartikel • Jun 17
Weekly Picks: 💊 VLS' Solvable Headwinds, VOS' Multi-Year Growth, and ISRG's Valuation Concerns
Why Vita Life Science’s is a solid business with solvable headwinds, how 2 massive tailwinds will drive multi-year growth for Vossloh, and why Intuitive Surgical’s strengths don’t outweigh the valuation risks.Analyseartikel • Jun 16
Unpleasant Surprises Could Be In Store For Intuitive Surgical, Inc.'s (NASDAQ:ISRG) Shares
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 17x, you may...Seeking Alpha • Apr 18
Intuitive Surgical: Too Many Rain Clouds Coming
Summary Intuitive Surgical dominates the growing robotic surgery market with a 60% share, but faces rising competition from Medtronic and Johnson & Johnson. Intuitive Surgical's high valuation (P/E ratio of 60x) makes it less attractive for new investors. The company boasts high margins, no debt, and strong revenue growth, but faces short-term challenges like import tariffs and competitive pressures. While ISRG is fundamentally strong, I recommend waiting for a more attractive entry point due to current high valuations and market risks. Read the full article on Seeking AlphaSeeking Alpha • Apr 11
Intuitive Surgical: Premium Valuation Meets Mounting Headwinds (Downgrade)
Summary Intuitive Surgical stock outperformed the S&P 500 since September 2024, with Q4 revenue growing 25% year-over-year to $2.41 billion. The installed base of da Vinci surgical systems grew 15% to 9,902 units, with recurring revenue constituting 84% of total revenue. Management forecasts procedure growth slowing from 17% to 13-16% in 2025, with margin pressure expected due to various factors. Despite strong market position and growth, ISRG trades at multiples over four times its peers and appears considerably overvalued on DCF analysis. Read the full article on Seeking AlphaNeues Narrativ • Mar 30
From Battle Field to Robotic Surgery
Intuitive Surgical (ISRG) is a pioneer in robotic-assisted surgery, revolutionizing the medical field with its da Vinci surgical system. Founded in 1995, the company has continuously innovated, makingNeues Narrativ • Mar 18
Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth
Increased Adoption of Robotic Surgery:Hospitals and surgical centers continue to adopt Intuitive Surgical’s da Vinci systems as clinical evidence shows improved outcomes and reduced recovery times.ExpSeeking Alpha • Mar 09
Intuitive Surgical: Getting Closed To Its Fair Value
Summary Intuitive Surgical is going through a temporary decrease in margins and returns on capital, but as the investment cycle approaches its end, profitability will increase. The company has been heavily investing in expanding production, AI, machine learning, and augmented reality, but CapEx will decrease in 2025. The CEO owns ~70 times its total yearly compensation, so there is a strong alignment between management and shareholders. While the stock is slightly overvalued, there might be an opportunity soon to buy into this outstanding business. Read the full article on Seeking AlphaSeeking Alpha • Jan 28
Intuitive Surgical: The Robot Is Well-Oiled
Summary Intuitive Surgical, with its Da Vinci robots, enjoys a great competitive position in minimally invasive surgery, driven by $6 billion in R&D and first-mover advantage. The business model, with 84% recurring revenue from instruments, accessories, and services, ensures stable growth and high margins, despite occasional stock volatility. Financially, ISRG boasts zero debt and $8.8 billion in cash, but declining margins and high valuation multiples make current stock prices hard to justify. While ISRG's growth prospects are strong, the current valuation suggests limited returns; thus, I cannot rate it a buy but also not a sell. Read the full article on Seeking AlphaSeeking Alpha • Jan 20
Intuitive Surgical: Second Half 2025 Guidance Is Critical To Maintaining Current Euphoria
Summary Intuitive Surgical's share price surged after the company reported 25% YoY revenue growth in the fourth quarter. Despite macro headwinds, robust procedure volumes, international expansion and new product rollouts continue to support growth. While investors probably should look through the current growth surge, particularly given Intuitive's extreme valuation, near term earnings beats could continue to drive the stock higher. Read the full article on Seeking AlphaSeeking Alpha • Dec 27
Intuitive Surgical: Growing Impressively, But It Appears Overvalued
Summary Intuitive Surgical's da Vinci system shows strong growth and innovation, but current valuation warrants a Hold rating due to potential overvaluation risks. The global robotics market is expanding, driven by aging populations and demand for minimally invasive procedures, benefiting Intuitive Surgical's recurring revenue model. Despite impressive financial metrics and growth, high P/E ratio and EV/Sales suggest caution, with intrinsic value calculations indicating potential overvaluation. Regulatory approvals and AI advancements promise future growth, but economic shocks and competitive threats could impact market share and investor confidence. Read the full article on Seeking AlphaSeeking Alpha • Nov 14
Intuitive Surgical: One Of The Best Business Models In The World, But Not At This Price
Summary Intuitive Surgical's da Vinci systems revolutionize minimally invasive surgery, offering superior precision, dexterity, and visualization, leading to better patient outcomes and efficiency. The business model thrives on recurring revenue from disposable instruments and maintenance, ensuring long-term cash flow predictability and resilience. Despite high valuations, Intuitive Surgical's technological superiority, lack of competition, and robust R&D investment justify its premium market position. Given the current overvaluation, I recommend holding shares and waiting for market corrections before buying, projecting a target price of $495 per share by 2030. Read the full article on Seeking AlphaSeeking Alpha • Oct 18
Intuitive Surgical Q3: Da Vinci 5 Robot Set For 2025, But Overvalued
Summary I reiterate a 'Sell' rating on Intuitive Surgical with a fair value of $350 per share due to its hefty valuation. The Da Vinci 5 robot rollout in mid-2025 is a major catalyst, with significant growth potential from innovative technology and positive surgeon feedback. Despite strong leadership and market position, ISRG's overvaluation and high WACC of 13% justify the 'Sell' rating. Key risks include potential stock repurchases and successful monetization of software, which could push the stock price higher in the future. Read the full article on Seeking AlphaSeeking Alpha • Sep 24
Intuitive Surgical Offers Low Risk, High Return Despite Valuation Concerns
Summary Intuitive Surgical remains a leader in robotic surgery despite intensifying competition from Medtronic and Johnson & Johnson. The company's da Vinci procedures grew 17% year-over-year, driving growth in system sales and recurring revenue. Intuitive Surgical reported strong Q2 2024 earnings, with $2.01 billion in revenue, surpassing analysts' estimates. The company's high valuation presents risk, though long-term prospects in the robotic surgery market remain favorable. I recommend a "buy" for ISRG due to its financial health, innovation in surgical robotics, and long-term growth outlook. Read the full article on Seeking AlphaSeeking Alpha • Aug 26
Intuitive Surgical: Detached From Fundamentals
Summary Against expectations of a growth slowdown, Intuitive Surgical's results have been strong in 2024, supported by robust procedure volumes and a solid da Vinci 5 launch. Intuitive Surgical's margins picked up in Q2 despite the scaling of da Vinci 5 sales. Margins will come under pressure in coming quarters though as additional costs begin to hit. Intuitive Surgical has a large competitive advantage and a long growth runway, but its valuation will make it difficult for the company to generate strong returns. Read the full article on Seeking Alpha
Neues Narrativ • Aug 20
Da Vinci 5 Launch And Digital Expansion Set To Revolutionize Surgical Efficiency And Drive Growth
Launch of da Vinci 5 systems and expansion in digital services like My Intuitive app show promise for revenue growth and operational efficiency.Seeking Alpha • Aug 20
Intuitive Surgical: A Lofty Price To Pay For Innovation, Wait For A Better Entry Point
Summary Intuitive Surgical dominates healthcare robotics with strong growth in its Da Vinci system, driving impressive procedure increases and recurring revenue. The company’s innovation, including the new Da Vinci 5, boosts sales, margins, and customer retention, solidifying its market position and long-term potential. Despite ISRG’s bright outlook, its high P/E ratio suggests the stock may be overpriced, making it prudent to wait for a better entry point before investing. Read the full article on Seeking AlphaSeeking Alpha • Jul 12
Intuitive Surgical: Shares Surge, But Now Near Fair Value (Rating Downgrade)
Summary ISRG has been outperforming medical device stocks and S&P 500 amid strong earnings growth and technical momentum. More EPS gains are expected over the coming quarters, but the valuation has become a concern. ISRG showing strong technical momentum, with shares breaking out above key resistance. Ahead of earnings next week, I highlight key price levels to watch. Read the full article on Seeking AlphaGewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 14,994 | 4,294 | 5,077 | 5,813 | 24 |
| 12/31/2027 | 13,262 | 3,733 | 4,407 | 4,989 | 32 |
| 12/31/2026 | 11,707 | 3,287 | 4,270 | 4,898 | 30 |
| 3/31/2026 | 10,582 | 2,979 | 2,834 | 3,361 | N/A |
| 12/31/2025 | 10,065 | 2,856 | 2,491 | 3,031 | N/A |
| 9/30/2025 | 9,612 | 2,747 | 2,271 | 2,961 | N/A |
| 6/30/2025 | 9,145 | 2,608 | 1,994 | 2,826 | N/A |
| 3/31/2025 | 8,715 | 2,476 | 1,745 | 2,731 | N/A |
| 12/31/2024 | 8,352 | 2,323 | 1,304 | 2,415 | N/A |
| 9/30/2024 | 7,867 | 2,243 | 586 | 1,821 | N/A |
| 6/30/2024 | 7,573 | 2,094 | 420 | 1,663 | N/A |
| 3/31/2024 | 7,319 | 1,988 | 596 | 1,708 | N/A |
| 12/31/2023 | 7,124 | 1,798 | 750 | 1,814 | N/A |
| 9/30/2023 | 6,851 | 1,517 | 1,256 | 2,023 | N/A |
| 6/30/2023 | 6,665 | 1,425 | 1,178 | 1,858 | N/A |
| 3/31/2023 | 6,431 | 1,312 | 1,006 | 1,639 | N/A |
| 12/31/2022 | 6,222 | 1,322 | 958 | 1,491 | N/A |
| 9/30/2022 | 6,118 | 1,378 | 1,091 | 1,621 | N/A |
| 6/30/2022 | 5,964 | 1,435 | 1,310 | 1,739 | N/A |
| 3/31/2022 | 5,906 | 1,644 | 1,460 | 1,835 | N/A |
| 12/31/2021 | 5,710 | 1,705 | 1,750 | 2,089 | N/A |
| 9/30/2021 | 5,489 | 1,689 | 1,885 | 2,149 | N/A |
| 6/30/2021 | 5,163 | 1,623 | 1,662 | 1,922 | N/A |
| 3/31/2021 | 4,551 | 1,173 | 1,315 | 1,610 | N/A |
| 12/31/2020 | 4,358 | 1,061 | 1,143 | 1,485 | N/A |
| 9/30/2020 | 4,307 | 1,053 | 988 | 1,410 | N/A |
| 6/30/2020 | 4,358 | 1,136 | 1,088 | 1,532 | N/A |
| 3/31/2020 | 4,604 | 1,386 | 1,202 | 1,618 | N/A |
| 12/31/2019 | 4,479 | 1,379 | N/A | 1,598 | N/A |
| 9/30/2019 | 4,247 | 1,314 | N/A | 1,384 | N/A |
| 6/30/2019 | 4,040 | 1,210 | N/A | 1,307 | N/A |
| 3/31/2019 | 3,850 | 1,147 | N/A | 1,223 | N/A |
| 12/31/2018 | 3,724 | 1,128 | N/A | 1,170 | N/A |
| 9/30/2018 | 3,570 | 804 | N/A | 1,164 | N/A |
| 6/30/2018 | 3,457 | 810 | N/A | 1,198 | N/A |
| 3/31/2018 | 3,306 | 778 | N/A | 1,183 | N/A |
| 12/31/2017 | 3,138 | 671 | N/A | 1,144 | N/A |
| 9/30/2017 | 3,003 | 906 | N/A | 1,142 | N/A |
| 6/30/2017 | 2,878 | 819 | N/A | 1,057 | N/A |
| 3/31/2017 | 2,790 | 780 | N/A | 1,102 | N/A |
| 12/31/2016 | 2,707 | 738 | N/A | 1,087 | N/A |
| 9/30/2016 | 2,619 | 722 | N/A | 1,041 | N/A |
| 6/30/2016 | 2,522 | 678 | N/A | 952 | N/A |
| 3/31/2016 | 2,434 | 628 | N/A | 875 | N/A |
| 12/31/2015 | 2,367 | 589 | N/A | 806 | N/A |
| 9/30/2015 | 2,285 | 546 | N/A | 683 | N/A |
| 6/30/2015 | 2,250 | 502 | N/A | 654 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ISRGDas prognostizierte Gewinnwachstum (12.6% pro Jahr) liegt über der Sparquote (3.5%).
Ertrag vs. Markt: ISRGDie Erträge des Unternehmens (12.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (16.8% pro Jahr).
Hohe Wachstumserträge: ISRGDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: ISRGDie Einnahmen des Unternehmens (11.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (11.7% pro Jahr).
Hohe Wachstumseinnahmen: ISRGDie Einnahmen des Unternehmens (11.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: ISRGDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (15.2%).
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/22 14:51 |
| Aktienkurs zum Tagesende | 2026/05/22 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Intuitive Surgical, Inc. wird von 56 Analysten beobachtet. 32 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| null null | Argus Research Company |
| David Toung | Argus Research Company |
| David Rescott | Baird |